5,7-Dihydroxy-2-isopropylchromone-8-beta-D-glucoside



Compound IDCDAMM02750
Common name5,7-Dihydroxy-2-isopropylchromone-8-beta-D-glucoside
IUPAC name5,7-dihydroxy-2-propan-2-yl-8-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
Molecular formulaC18H22O9

Experimental data

Retention time10.78
Adduct[M+H]+
Actual mz383.128
Theoretical mz383.133
Error14.29
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.3007

Identifiers and class information

Inchi keyGFMIWSFTWTWABA-MWVKZTPQNA-N
SmilesO=C1C=C(OC=2C1=C(O)C=C(O)C2C3OC(CO)C(O)C(O)C3O)C(C)C
SuperclassOrganic oxygen compounds
ClassOrganooxygen compounds

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)8
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)382.366
Computed dipole moment(dipole)7.234
Total solvent accessible surface area (SASA)580.15
Hydrophobic component of SASA (FOSA)211.178
Hydrophilic component of SASA (FISA)285.291
Pie component of the SASA (PISA)83.681
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1075.92
Number of hydrogen bond donors (donorHB)5
Number of hydrogen bond acceptors (accptHB)11.5
Free energy of solvation of dipole (dip^2/V)0.0486417
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0443243
Globularity descriptor (glob)0.875276
Predicted polarizability in cubic angstroms (QPpolrz)32.567
Predicted hexadecane/gas partition coefficient (QPlogPC16)12.033
Predicted octanol/gas partition coefficient (QPlogPoct)25.26
Predicted water/gas partition coefficient (QPlogPw)20.511
Predicted octanol/water partition coefficient (QPlogPo/w)-0.696
Predicted aqueous solubility (QPlogS)-2.31
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.114
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.949
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)19.52
Predicted brain/blood partition coefficient (QPlogBB)-2.401
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)7.024
Predicted skin permeability, log Kp (QPlogKp)-5.715
PM3 calculated ionization potential (IP(ev))9.258
PM3 calculated electron affinity (EA(eV))0.379
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.676
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)33.01
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)160.654
Number of nitrogen and oxygen atoms (#NandO)9
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
O43570CA12Carbonic anhydrase XIIT16987SwissTargetPrediction
P43166CA7Carbonic anhydrase VIIT37541SwissTargetPrediction
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction
P24864CCNE1Cyclin-dependent kinase 2/cyclin E1T10052SEA
P08253MMP2Matrix metalloproteinase 2T68251SwissTargetPrediction
P14780MMP9Matrix metalloproteinase 9T54156SwissTargetPrediction
P03372ESR1Estrogen receptor alphaT02506SwissTargetPrediction
P24941CDK2Cyclin-dependent kinase 2T70176SEA
P11387TOP1DNA topoisomerase IT09826SEA
P24385CCND1Cyclin-dependent kinase 4/cyclin D1T12355SEA
P32320CDACytidine deaminase (by homology)T79027SEA
Q99808SLC29A1Equilibrative nucleoside transporter 1T13491SwissTargetPrediction
Q07002CDK18Serine/threonine-protein kinase PCTAIRE-3T27577SEA
P01112HRASTransforming protein p21/H-Ras-1T71081SEA
P60568IL2Interleukin-2T61698SEA
P14679TYRTyrosinaseT97035SEA
P20248CCNA2CDK2/Cyclin AT58470SEA
Q14004CDK13Cyclin-dependent kinase 13T74839SEA
Q8N5S9CAMKK1CaM-kinase kinase alphaT38134SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
Q09013DMPKMyotonin-protein kinaseT68766SEA
P05231IL6Interleukin-6T32578SEA
P21860ERBB3Receptor tyrosine-protein kinase erbB-3T86350SEA
Q13705ACVR2BActivin receptor type-2BT80338SEA
P27037ACVR2AActivin receptor type IIAT47366SEA
P14635CCNB1G2/mitotic-specific cyclin B1T98459SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T68251DI0238Lung cancer[ICD-11: 2C25]P08253MMP2
T54156DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P14780MMP9
T54156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P14780MMP9
T54156DI0395Stomach cancer[ICD-11: 2B72]P14780MMP9
T54156DI0419Ulcerative colitis[ICD-11: DD71]P14780MMP9
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T70176DI0060Brain cancer[ICD-11: 2A00]P24941CDK2
T70176DI0062Breast cancer[ICD-11: 2C60-2C6Y]P24941CDK2
T70176DI0238Lung cancer[ICD-11: 2C25]P24941CDK2
T70176DI0241Lymphoma[ICD-11: 2A80-2A86]P24941CDK2
T70176DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P24941CDK2
T70176DI0303Non-small-cell lung cancer[ICD-11: 2C25]P24941CDK2
T70176DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P24941CDK2
T70176DI0406Thymoma[ICD-11: 2C27]P24941CDK2
T09826DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P11387TOP1
T09826DI0095Colorectal cancer[ICD-11: 2B91]P11387TOP1
T09826DI0238Lung cancer[ICD-11: 2C25]P11387TOP1
T09826DI0321Ovarian cancer[ICD-11: 2C73]P11387TOP1
T09826DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P11387TOP1
T12355DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P24385CCND1
T79027DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P32320CDA
T13491DI0030Angina pectoris[ICD-11: BA40]Q99808SLC29A1
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T58470DI0363Retina cancer[ICD-11: 2D02]P20248CCNA2
T74839DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q14004CDK13
T68766DI0288Myotonic disorder[ICD-11: 8C71]Q09013DMPK
T32578DI0028Anemia[ICD-11: 3A00-3A9Z]P05231IL6
T86350DI0062Breast cancer[ICD-11: 2C60-2C6Y]P21860ERBB3
T86350DI0095Colorectal cancer[ICD-11: 2B91]P21860ERBB3
T86350DI0172Head and neck cancer[ICD-11: 2D42]P21860ERBB3
T86350DI0238Lung cancer[ICD-11: 2C25]P21860ERBB3
T86350DI0246Malignant mesenchymal neoplasm[ICD-11: 2B5D-2B5Y]P21860ERBB3
T86350DI0259Metastatic lymph node neoplasm[ICD-11: 2D60]P21860ERBB3
T86350DI0326Pancreatic cancer[ICD-11: 2C10]P21860ERBB3
T86350DI0351Psoriasis[ICD-11: EA90]P21860ERBB3
T86350DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P21860ERBB3
T86350DI0393Squamous cell carcinoma[ICD-11: 2B60-2D01]P21860ERBB3
T80338DI0295Nervous system paraneoplastic/autoimmune disorder[ICD-11: 8E4A]Q13705ACVR2B
T47366DI0012Acute myeloid leukaemia[ICD-11: 2A60]P27037ACVR2A
T47366DI0198Idiopathic inflammatory myopathy[ICD-11: 4A41]P27037ACVR2A

Copyright © 2025